** Shares of cancer drugmaker Exelixis EXEL.O fall 2.3% to $36.83
** US FDA approved EXEL's cancer drug, Cabometyx, for treating adult and pediatric patients with previously treated advanced neuroendocrine tumors $(NET)$
** Citizens Bank analyst Silvan Tuerkcan notes EXEL's shares declined as investors had already factored the approval into the stock price
** Tuerkcan says investor focus will now be on the launch of the drug for patients with NET, and size of the opportunity, which is expected to drive "a significant portion" of the company's sales growth in the near term
** Leerink Partners analyst Andrew Berens estimates Cabometyx to bring in $75 million for NET in 2025, with peak sales reaching $750 million before losing exclusivity impact starting in 2030
** Stock gained ~59% in the last 12 months
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.